Table 1.
Clinical characteristics of the study population.
| Variables | No NOAF group (n = 539) | NOAF group (n = 41) | p-Value |
|---|---|---|---|
| Age, years | 61 (42–78) | 64 (45–79) | 0.021 |
| Gender (male), n (%) | 360 (66.8) | 28 (68.3) | 0.84 |
| Current smoker, n (%) | 216 (40.1) | 14 (34.1) | 0.51 |
| Alcohol use, n (%) | 110 (20.4) | 12 (29.3) | 0.23 |
| Diabetes mellitus, n (%) | 226 (41.9) | 25 (61.0) | 0.02 |
| Hypertension, n (%) | 299 (55.5) | 30 (73.2) | 0.03 |
| Dyslipidemia on admission, n (%) | 188 (34.9) | 16 (39.0) | 0.61 |
| Previous stroke, n (%) | 32 (5.9) | 4 (9.8) | 0.31 |
| Previous MI, n (%) | 34 (6.3) | 3 (7.3) | 0.74 |
| Previous PCI, n (%) | 22 (4.1) | 3 (7.3) | 0.41 |
| Family history of CAD, n (%) | 102 (18.9) | 10 (24.4) | 0.41 |
| Peripheral vascular disease, n (%) | 43 (8.0) | 5 (12.2) | 0.37 |
| BMI, kg/m2 | 24.5 ± 3.1 | 24.7 ± 1.9 | 0.65 |
| Sleep apnea, n (%) | 52 (9.6) | 5 (12.2) | 0.59 |
| Killip ≥2, n (%) | 102 (18.9) | 16 (39.0) | <0.01 |
| Medication history | |||
| ACEI/ARB, n (%) | 380 (70.5) | 30 (73.2) | 0.86 |
| Beta-blocker, n (%) | 322 (59.7) | 26 (63.4) | 0.74 |
| Statins, n (%) | 532 (98.7) | 40 (97.6) | 0.55 |
| Calcium channel blockers, n (%) | 141 (26.2) | 15 (36.6) | 0.15 |
| Diuretics, n (%) | 103 (19.1) | 9 (22.0) | 0.68 |
| Echocardiographic analysis | |||
| LA, mm | 32.6 ± 4.8 | 35.7 ± 6.5 | <0.01 |
| LVEDV, mm | 102.5 ± 22.0 | 106.8 ± 34.9 | 0.24 |
| LVESV, mm | 59.2 ± 15.6 | 63.5 ± 28.3 | 0.12 |
| LVEF (%) | 42.5 ± 6.0 | 42.2 ± 6.8 | 0.80 |
| Laboratory analysis | |||
| NT-proBNP, pg/mL | 3,512.8 ± 5,883.3 | 5,487.7 ± 7,071.3 | 0.04 |
| CRP, mg/L | 7.6 ± 8.0 | 12.0 ± 7.3 | <0.01 |
| Creatine kinase, U/L | 88.1 ± 48.4 | 84.0 ± 25.8 | 0.59 |
| sST2, ng/mL | 48.7 ± 23.6 | 71.5 ± 34.8 | <0.01 |
MI, myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker, LA, left atrium; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVEF, left ventricular ejection fraction; CRP, C-reactive protein; sST2, soluble ST2.